Company Overview: Fibrocell

Industry News

12 Jun

Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma

EXTON, Pa., June 12, 2017 (GLOBE NEWSWIRE) — Fibrocell Science, Inc., (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to FCX-013, Fibrocell’s gene therapy...

Read more

17 May

Fibrocell to Present at Inaugural Cell & Gene Exchange 2017

EXTON, Pa., May 17, 2017 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, Chief Executive Officer, will present at the inaugural Cell & Gene Exchange 2017 on Monday, May...

Read more

9 May

Fibrocell and Intrexon Announce Two Oral Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy

EXTON, Pa. and GERMANTOWN, Md., May 09, 2017 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, and Intrexon Corporation (XON), a leader in synthetic biology, announced today that two abstracts will be presented in...

Read more

8 May

Fibrocell Announces Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

EXTON, Pa., May 08, 2017 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, announced today that the Data Safety Monitoring Board (DSMB) has recommended continuation of the Phase 1/2 clinical trial of FCX-007 for...

Read more

3 May

Fibrocell to Host Conference Call and Webcast on Wednesday, May 10, 2017 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights

EXTON, Pa., May 03, 2017 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2017 and recent operational highlights on Wednesday, May 10, 2017,...

Read more

28 Mar

Fibrocell Regains Compliance with NASDAQ Listing Requirements

EXTON, Pa., March 28, 2017 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on March 27, 2017 indicating that the Company...

Read more

26 Jul

Fibrocell

The Leader in Autologous Fibroblast Therapies At the forefront of personalized biologics Fibrocell, a cell and gene therapy company, is focused on diseases affecting the skin and connective tissue. Our approach to personalized biologics is distinctive based on our proprietary autologous fibroblast technology. By extracting fibroblast cells from a...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address